Professional
Added to YB: 2025-11-03
Pitch date: 2025-09-30
JNJ [neutral]
Johnson & Johnson
+31.07%
current return
Author Info
No bio for this author
Company Info
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Market Cap
$585.4B
Pitch Price
$183.85
Price Target
N/A
Dividend
2.14%
EV/EBITDA
18.06
P/E
22.03
EV/Sales
6.53
Sector
Pharmaceuticals
Category
growth
Meridian Hedged Equity Fund Portfolio Holding: Johnson & Johnson
JNJ (holding update): Major healthcare co navigating Stelara patent cliff w/ robust oncology/immunology pipeline. FDA approved Inlexzo for bladder cancer, Rybrevant lung cancer drug showing promise w/ injection format. Strong sales momentum offsetting Stelara decline, favorable talc litigation developments.
Read full article (1 min)